Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,764,632
  • Shares Outstanding, K 647,270
  • Annual Sales, $ 22,849 M
  • Annual Income, $ 1,979 M
  • 36-Month Beta 1.40
  • Price/Sales 5.49
  • Price/Cash Flow 12.56
  • Price/Book 8.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 3.42
  • Number of Estimates 10
  • High Estimate 3.75
  • Low Estimate 3.12
  • Prior Year 3.27
  • Growth Rate Est. (year over year) +4.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
192.38 +2.15%
on 10/11/18
210.19 -6.50%
on 09/27/18
-4.06 (-2.02%)
since 09/14/18
3-Month
189.16 +3.89%
on 07/23/18
210.19 -6.50%
on 09/27/18
+0.61 (+0.31%)
since 07/13/18
52-Week
163.31 +20.34%
on 04/02/18
210.19 -6.50%
on 09/27/18
+13.51 (+7.38%)
since 10/13/17

Most Recent Stories

More News
Immune Design to Halt Cancer Vaccine Program, Shares Plunge

Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.

MRK : 70.05 (+0.34%)
IMDZ : 1.74 (-5.88%)
RHHBY : 29.7400 (+0.15%)
AMGN : 196.52 (-0.44%)
Top Ranked Income Stocks to Buy for October 15th

Top Ranked Income Stocks to Buy for October 15th

AB : 29.60 (+1.37%)
ADM : 49.16 (+0.68%)
AEP : 71.07 (+0.24%)
AMGN : 196.52 (-0.44%)
AbbVie Settles With Novartis to Delay Humira Biosimilar in US

AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

MYL : 32.04 (-0.22%)
NVS : 83.56 (+0.94%)
ABBV : 89.72 (-1.07%)
AMGN : 196.52 (-0.44%)
Look for Shares of Amgen Inc to Potentially Rebound after Yesterday's 1.65% Sell Off

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $194.28 to a high of $202.96. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $200.77...

AMGN : 196.52 (-0.44%)
J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings

The positive trend seen in J&J's (JNJ) pharma segment sales is likely to continue in the third quarter.

MRK : 70.05 (+0.34%)
JNJ : 134.82 (+0.71%)
VRTX : 179.62 (-0.94%)
AMGN : 196.52 (-0.44%)
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.

NVS : 83.56 (+0.94%)
RHHBY : 29.7400 (+0.15%)
AMGN : 196.52 (-0.44%)
BIIB : 328.78 (-0.65%)
Tilary Buys Alef Biotechnology to Build Base in Latin America

Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.

STZ : 225.79 (+0.04%)
TLRY : 159.02 (+7.23%)
AMGN : 196.52 (-0.44%)
CGC : 54.54 (+9.52%)
FDA Sets Action Date for Recro's Pain Management Candidate

The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

CRSP : 35.67 (-5.38%)
AMGN : 196.52 (-0.44%)
ALKS : 41.40 (-0.58%)
REPH : 6.86 (+3.00%)
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis

Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.

CRSP : 35.67 (-5.38%)
MRUS : 16.06 (+2.23%)
BHC : 24.74 (+0.32%)
AMGN : 196.52 (-0.44%)
Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

KALA : 8.61 (+0.58%)
AMGN : 196.52 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 200.48
1st Resistance Point 198.93
Last Price 196.52
1st Support Level 195.00
2nd Support Level 192.61

See More

52-Week High 210.19
Last Price 196.52
Fibonacci 61.8% 192.28
Fibonacci 50% 186.75
Fibonacci 38.2% 181.22
52-Week Low 163.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar